Cubicin Related Published Studies
Well-designed clinical trials related to Cubicin (Daptomycin)
Clinical experience with daptomycin: bacteraemia and endocarditis. [2008.11]
Daptomycin for endocarditis and/or bacteraemia: a systematic review of the experimental and clinical evidence. [2007.07]
Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. [2006.10]
Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. [2006.08.17]
Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. [2005.02]
The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. [2004.06.15]
Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers. [1992.02]
Ex vivo study of serum bactericidal titers and killing rates of daptomycin (LY146032) combined or not combined with amikacin compared with those of vancomycin. [1989.10]
Other research related to Cubicin (Daptomycin)
Daptomycin in endocarditis and bacteraemia: a British perspective. [2008.11]
Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates. [2008.09.08]
A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria. [2008.09]
Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations. [2008.09]
Abiotrophia spp. and Staphylococcus epidermidis endocarditis treated with daptomycin. [2008.08.08]
Outpatient parenteral antibiotic therapy with daptomycin: insights from a patient registry. [2008.08]
Daptomycin, a lipopeptide antibiotic in clinical practice. [2008.08]
Daptomycin non-susceptible meticillin-resistant Staphylococcus aureus USA 300 isolate. [2008.08]
A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria. [2008.07.25]
Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus. [2008.07]
Evaluation of daptomycin pharmacodynamics and resistance at varying dosage regimens against Staphylococcus aureus with reduced susceptibilities to daptomycin in an in-vitro pharmacodynamic model with simulated endocardial vegetations. [2008.06.30]
Activities of clindamycin, daptomycin, doxycycline, linezolid, trimethoprim-sulfamethoxazole, and vancomycin against community-associated methicillin-resistant Staphylococcus aureus with inducible clindamycin resistance in murine thigh infection and in vitro pharmacodynamic models. [2008.06]
High rate of decreasing daptomycin susceptibility during the treatment of persistent Staphylococcus aureus bacteremia. [2008.06]
Daptomycin-induced acute renal and hepatic toxicity without rhabdomyolysis. [2008.05]
Successful treatment of vancomycin-resistant Enterococcus faecium pyelonephritis with daptomycin during pregnancy. [2008.05]
Pharmacokinetic evaluation of single-dose intravenous daptomycin in patients with thermal burn injury. [2008.05]
Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia. [2008.04.15]
The use of daptomycin for Staphylococcus aureus infections in critical care medicine. [2008.04]
Single-dose pharmacokinetics of daptomycin in children with suspected or proved gram-positive infections. [2008.04]
Diminished vancomycin and daptomycin susceptibility during prolonged bacteremia with methicillin-resistant Staphylococcus aureus. [2008.04]
Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan. [2008.03]
Daptomycin: a new treatment for insidious infections due to gram-positive pathogens. [2008.02.23]
Activity of daptomycin and selected antimicrobial agents tested against Staphylococcus aureus from patients with bloodstream infections hospitalized in European medical centers. [2008.02]
Clinical experience with daptomycin for the treatment of patients with documented gram-positive septic arthritis. [2008.02]
Clinical Experience with Daptomycin for the Treatment of Patients with Documented Gram-Positive Septic Arthritis (February). [2008.01.22]
Outcomes with daptomycin versus standard therapy for osteoarticular infections associated with Staphylococcus aureus bacteraemia. [2008.01]
Methicillin-resistant Staphylococcus aureus (MRSA) mitral valve acute bacterial endocarditis (ABE) in a patient with Job's syndrome (hyperimmunoglobulin E syndrome) successfully treated with linezolid and high-dose daptomycin. [2008.01]
Interaction of daptomycin with two recombinant thromboplastin reagents leads to falsely prolonged patient prothrombin time/International Normalized Ratio results. [2008.01]
Evaluation of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycin. [2008.01]
Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding. [2008.01]
Daptomycin: a review 4 years after first approval. [2008]
[New drugs; daptomycin] [2007.12.15]
Daptomycin therapy for invasive Gram-positive bacterial infections in children. [2007.12]
Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes. [2007.12]
Failure of daptomycin monotherapy for endocarditis caused by an Enterococcus faecium strain with vancomycin-resistant and vancomycin-susceptible subpopulations and evidence of in vivo loss of the vanA gene cluster. [2007.11.15]
In vitro activity of daptomycin and tigecycline against coagulase-negative staphylococcus blood isolates from bone marrow transplant recipients. [2007.11]
Community-phenotype-methicillin-resistant Staphylococcus aureus infections: a retrospective chart review of outcomes after treatment with daptomycin. [2007.11]
E. faecalis vancomycin-sensitive enterococcal bacteremia unresponsive to a vancomycin tolerant strain successfully treated with high-dose daptomycin. [2007.11]
Postmarketing clinical experience in patients with skin and skin-structure infections treated with daptomycin. [2007.10]
Cubicin Outcomes Registry and Experience (CORE) methodology. [2007.10]
Daptomycin in the treatment of patients with infective endocarditis: experience from a registry. [2007.10]
Daptomycin in the treatment of bacteremia. [2007.10]
Clinical experience with daptomycin for the treatment of patients with osteomyelitis. [2007.10]
Daptomycin and tigecycline: a review of clinical efficacy in the antimicrobial era. [2007.10]
Perspectives on Daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. [2007.09.01]
Daptomycin use after vancomycin-induced neutropenia in a patient with left-sided endocarditis. [2007.09]
Effectiveness and duration of daptomycin therapy in resolving clinical symptoms in the treatment of complicated skin and skin structure infections. [2007.09]
Daptomycin. [2007.09]
Daptomycin for treatment of patients with bone and joint infections: a systematic review of the clinical evidence. [2007.09]
[Daptomycin: revitalizing a former drug due to the need of new active agents against grampositive multiresistant bacterias] [2007.09]
Elution behavior of daptomycin-loaded calcium sulfate pellets: a preliminary study. [2007.08]
Clinical experience with daptomycin treatment of foot or ankle osteomyelitis: a preliminary study. [2007.08]
Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004). [2007.08]
Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin. [2007.08]
Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies. [2007.08]
Bacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus: the potential role of daptomycin. [2007.08]
Daptomycin for eradication of a systemic infection with a methicillin-resistant-Staphylococcus aureus in a biventricular assist device recipient. [2007.07]
Prevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis. [2007.06]
A febrile neutropenic patient with Enterococcus gallinarum sepsis treated with daptomycin and gentamicin. [2007.06]
Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients. [2007.06]
Daptomycin produces an enhanced bactericidal activity compared to ceftriaxone, measured by [3H]choline release in the cerebrospinal fluid, in experimental meningitis due to a penicillin-resistant pneumococcal strain without lysing its cell wall. [2007.06]
Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. [2007.05]
Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria. [2007.05]
Outcomes analysis of daptomycin use in a community hospital. [2007.05]
Daptomycin: a rapidly bactericidal lipopeptide for the treatment of Gram-positive infections. [2007.04]
Organizing pneumonia and pulmonary eosinophilic infiltration associated with daptomycin. [2007.04]
Eosinophilic pneumonia induced by daptomycin. [2007.04]
Prevention of Brain Injury by the Non Bacteriolytic Antibiotic Daptomycin in Experimental Pneumococcal Meningitis. [2007.03.19]
Bactericidal activity of daptomycin, vancomycin, teicoplanin and linezolid against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium using human peak free serum drug concentrations. [2007.03]
Infective endocarditis caused by daptomycin-resistant Enterococcus faecalis: a case report. [2007]
Fixed-dose combination lercanidipine/enalapril. [2007]
Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients. [2006.12.22]
Efficacy of daptomycin in complicated skin and skin-structure infections due to methicillin-sensitive and -resistant Staphylococcus aureus: results from the CORE Registry. [2006.12]
Bactericidal agents in the treatment of MRSA infections--the potential role of daptomycin. [2006.12]
Efficacy of daptomycin in the treatment of experimental endocarditis due to susceptible and multidrug-resistant enterococci. [2006.12]
[Daptomycin, the first cydal antibiotic of a new class active against Gram positive pathogens] [2006.12]
Management of cSSTIs: the role of daptomycin. [2006.11]
Serum Bactericidal Activities of High-Dose Daptomycin with and without Coadministration of Gentamicin against Isolates of Staphylococcus aureus and Enterococcus species. [2006.11]
Mechanisms of daptomycin resistance in Staphylococcus aureus. [2006.10]
Uncertain efficacy of daptomycin for prosthetic joint infections: a prospective case series. [2006.10]
[Daptomycin--a new antibiotic for the treatment of skin and soft tissue infections] [2006.09.21]
Multicenter evaluation of the Etest and disk diffusion methods for differentiating daptomycin-susceptible from non-daptomycin-susceptible Staphylococcus aureus isolates. [2006.09]
Development of daptomycin resistance in a bone marrow transplant patient with vancomycin-resistant Enterococcus durans. [2006.09]
Rhabdomyolysis during therapy with daptomycin. [2006.06.15]
The protein-binding and drug release properties of macromolecular conjugates containing daptomycin and dextran. [2006.06.06]
Pharmacokinetics of daptomycin in a critically ill adolescent with vancomycin-resistant enterococcal endocarditis. [2006.05]
Pacemaker-induced Staphylococcus aureus mitral valve acute bacterial endocarditis complicated by persistent bacteremia from a coronary stent: Cure with prolonged/high-dose daptomycin without toxicity. [2006.05]
Evaluation of high-dose daptomycin for therapy of experimental Staphylococcus aureus foreign body infection. [2006.04.11]
Daptomycin is more efficacious than vancomycin against a methicillin-susceptible Staphylococcus aureus in experimental meningitis. [2006.04]
Diminished susceptibility to daptomycin accompanied by clinical failure in a patient with methicillin-resistant Staphylococcus aureus bacteremia. [2006.03]
Using vancomycin concentrations for dosing daptomycin in a morbidly obese patient with renal insufficiency. [2006.03]
Daptomycin for the treatment of gram-positive bacteremia and infective endocarditis: a retrospective case series of 31 patients. [2006.03]
The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria. [2006.03]
|
